Scientific Program

Program days will run as scheduled, on Central European Time (CET Time Zone) – UTC +1
Day 1, March 2nd
13:00-13:15 Opening welcome
Congress co-chairs
13:15-14:15 Keynote Lectures
13:15-13:45 Advancements in AML immunotherapy:
He Huang, China
13:45-14:15 Predicting response to CAR T cells in LBCL:
Arnon Nagler, Israel
14:15-15:45 Session 1: Innovation in Immunotherapy
14:15-14:35 Linking the microbiome to CAR T cells responses:
Florent Malard, France
14:35-14:55 Cytokine release syndrome after CAR T therapy:
Yongxian Hu, China
14:55-15:15 CAR T treatment related to refractory/relapsed multiple myeloma:
Mingming Zhang, China
15:15-15:35 Exploring the value of point-of-care development:
Alvaro Urbano-Ispizua, Spain
15:35-15:45 Panel discussion
15:45-17:15 Session 2: Advanced Cellular Therapies
15:45-16:05 Will allogeneic CAR T cells revolutionize immunotherapy?
Bhagirathbhai Dholaria, USA
16:05-16:25 Exploring the advantages of CAR NK cells over CAR T cells:
Rizwan Romee, USA
16:25-16:45 The promise of induced pluripotent stem cells-derived CAR-immune cells:
Jin Zhang, China
16:45-17:05 DESCAR-T data on the use of Axi Cel as a 2nd line treatment option for patients with LBCL:
Gabriel Brisou, France
17:05-17:15 Panel discussion
Day 2, March 3rd
13:00-14:20 Session 3: Disease-Specific Focus
13:00-13:20 Targeting solid tumors: selecting an example (e.g., gastric, pancreatic, glioblastoma, or liver cancer):
Dongrui Wang, China
13:20-13:40 First-line treatment strategies for relapsed DLBCL:
Rémy Duléry, USA
13:40-14:00 Multiple myeloma: timing and approaches:
Mohamad Mohty, France
14:00-14:20 Panel discussion
14:20-15:40 Session 4: Practical Management in Immunotherapy
14:20-14:40 Strategies for preventing and treating CRS/ICANS in older patients:
Antoine Capes, France
14:40-15:00 Infectious complications after CAR T cells:
Eolia Brissot, France
15:00-15:20 CAR T cells hematotoxicity – Is inflammation the key?
Marion Subklewe, Germany
15:20-15:40 Panel discussion
15:40-16:30 Session 5: Specific Approaches
15:40-16:00 Allogeneic HSCT as consolidation after immunotherapy: donor selection and personalized therapy:
Yishan Ye, China
16:00-16:20 Strategies to prevent toxicities after CAR T cell therapy:
Jordan Gauthier, USA
16:20-16:30 Panel discussion
16:30-17:00 Closing Lecture
From transplantation to CAR T: what have we learned?
Didier Blaise, France
17:00-17:15 Summing-up remarks
Congress co-chairs